CRON
HealthcareCronos Group Inc. · Drug Manufacturers - Specialty & Generic · $1B
What is Cronos Group Inc.?
Cronos Group is a Canadian cannabinoid company operating across both the cannabis and hemp-derived consumer product markets. It serves medical, adult-use, and wellness consumers through multiple brands and channels.
Cronos generates revenue by cultivating, manufacturing, and distributing cannabis products — including dried flower, pre-rolls, edibles, and extracts — under its PEACE NATURALS and Spinach brands. It also sells hemp-derived supplements and cosmetics through the Lord Jones and Happy Dance brands via e-commerce and retail in the United States, and exports cannabis products to Germany, Israel, and Australia.
Cronos Group was founded in 2012 and is headquartered in Toronto, Canada.
- Medical and adult-use cannabis (PEACE NATURALS, Spinach)
- Hemp-derived supplements and cosmetics (Lord Jones, Happy Dance)
- Cannabis extracts, edibles, and concentrates
- International cannabis exports
Is CRON a Good Stock to Buy?
UQS Score rates CRON as Below Average overall.
The Risk pillar stands out as a relative bright spot, suggesting the balance sheet carries less financial danger than many cannabis-sector peers. The Growth and Valuation pillars also register positively, indicating the business has expansion potential and is not obviously overpriced relative to fundamentals.
Quality and Moat are both rated Weak, reflecting limited earnings consistency and a lack of durable competitive advantages in a crowded, heavily regulated market.
See the full pillar breakdown and underlying financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does CRON pay dividends?
No — Cronos Group Inc. does not currently pay a dividend.
Cronos Group does not currently pay a dividend. As a growth-stage cannabis company, capital is directed toward expanding operations, building brand presence, and navigating a complex regulatory environment rather than returning cash to shareholders.
When does CRON report earnings?
Cronos Group reports earnings on a quarterly cadence, consistent with standard practice for publicly listed equities.
Revenue trends reflect the company's dual focus on Canadian cannabis and US hemp-derived consumer products. Results can vary meaningfully quarter to quarter given regulatory shifts and evolving consumer demand across its markets.
For the most recent quarter's results, visit Cronos Group's investor relations page directly.
CRON Price History
-69.7% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Cronos Group Inc.?
Based on Cronos Group Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does Cronos Group do?
Cronos Group cultivates and sells cannabis products — including dried flower, pre-rolls, edibles, and extracts — in Canada and internationally. It also markets hemp-derived supplements and cosmetics in the United States under the Lord Jones and Happy Dance brands.
Does CRON pay dividends?
No, Cronos Group does not pay a dividend. The company is in a growth phase and reinvests available capital into its operations and brand development rather than distributing cash to shareholders.
When does CRON report earnings?
Cronos Group follows a standard quarterly reporting schedule. Because specific dates can shift, check the company's investor relations page for the most current earnings calendar.
Is CRON a good stock to buy?
The UQS Score rates CRON as Below Average. Growth and Risk pillars show relative strength, but weak Quality and Moat scores highlight meaningful challenges. Investors should review the full pillar analysis before drawing conclusions.
Is CRON overvalued?
The UQS Valuation pillar for CRON is rated Good, suggesting the stock does not appear significantly overpriced relative to its fundamentals. The complete valuation metrics are available to UQS Pro members.
What is CRON's market cap bracket?
Cronos Group is classified as a small-cap stock, meaning its total market value is relatively modest compared to large or mega-cap peers in the broader healthcare and consumer sectors.
Is CRON a long-term quality investment?
As a long-term quality indicator, CRON's Below Average UQS Score — driven by Weak Quality and Moat ratings — suggests the business has not yet demonstrated the consistency or competitive durability typically associated with high-quality long-term holdings.
What sector does CRON belong to?
Cronos Group is classified under the Healthcare sector, reflecting its focus on cannabis and cannabinoid-derived products for medical and wellness applications, alongside its consumer-facing adult-use and cosmetics businesses.
Unlock Full CRON Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar ratings
- ✓Access underlying financial metrics driving each pillar
- ✓Compare CRON against sector peers on quality and valuation
- ✓Get the complete analyst-style breakdown in one place
Pro Analysis
CRON — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | 44.8 | 2.1 | 19.0 | 66.8 | 100.0 | 74.3 | -0.1 |
| May 21, 2026 | 44.9 | 2.1 | 19.0 | 66.8 | 100.0 | 74.8 | 0.0 |
| May 20, 2026 | 44.9 | 2.1 | 19.0 | 66.8 | 100.0 | 75.2 | 0.0 |
| May 16, 2026 | 44.9 | 2.1 | 19.0 | 66.8 | 100.0 | 75.0 | +0.1 |
| May 14, 2026 | 44.8 | 2.1 | 19.0 | 66.8 | 100.0 | 74.4 | +1.7 |
| May 13, 2026 | 43.1 | 2.1 | 19.0 | 59.5 | 100.0 | 72.9 | -1.4 |
| May 12, 2026 | 44.5 | 2.1 | 19.0 | 65.1 | 100.0 | 74.8 | +0.1 |
| May 11, 2026 | 44.4 | 2.1 | 19.0 | 76.4 | 82.4 | 76.9 | +0.5 |
| May 10, 2026 | 43.9 | 0.0 | 19.0 | 76.4 | 82.4 | 76.7 | +0.8 |
| May 8, 2026 | 43.1 | 0.0 | 19.0 | 76.4 | 82.4 | 71.1 | -0.7 |
CRON — Pillar Breakdown
Quality
— 2.1/100 (25%)Cronos Group Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 66.8/100 (20%)Cronos Group Inc. demonstrates healthy growth trends across revenue and earnings.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 100.0/100 (15%)Cronos Group Inc. carries minimal financial risk with conservative leverage and strong solvency.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 75.1/100 (15%)Cronos Group Inc. appears attractively valued relative to its earnings, cash flows, and sector peers.
Inverse of forward P/E — higher yield means cheaper stock.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 19/100 (25%)Cronos Group Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for CRON.
Score Composition
Financial Data
More Stock Analysis
How is the CRON UQS Score Calculated?
The UQS (Unified Quality Score) for Cronos Group Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Cronos Group Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Cronos Group Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.